Teacher Retirement System of Texas Reduces Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Teacher Retirement System of Texas lowered its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 8.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 34,857 shares of the company’s stock after selling 3,321 shares during the quarter. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were worth $474,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of DNLI. Charles Schwab Investment Management Inc. boosted its stake in Denali Therapeutics by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,462 shares of the company’s stock worth $20,960,000 after buying an additional 12,652 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of Denali Therapeutics in the fourth quarter valued at $514,000. Raymond James Financial Inc. bought a new stake in shares of Denali Therapeutics in the 4th quarter worth about $533,000. PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after acquiring an additional 885 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Denali Therapeutics by 33.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,757 shares of the company’s stock worth $810,000 after purchasing an additional 10,038 shares during the period. Institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNLI. Wedbush reduced their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. William Blair upgraded Denali Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. Bank of America decreased their price target on Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, May 19th. HC Wainwright dropped their price objective on Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald upgraded Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Buy” and an average price target of $33.71.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $14.87 on Thursday. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -5.57 and a beta of 1.33. The firm’s 50-day moving average is $14.24 and its two-hundred day moving average is $16.47. Denali Therapeutics Inc. has a 1 year low of $10.57 and a 1 year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same quarter in the previous year, the company posted ($0.68) EPS. On average, equities analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total value of $7,429,230.00. Following the transaction, the chief executive officer directly owned 253,071 shares in the company, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 12.50% of the company’s stock.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.